Top Markets
#1 Akedo Akedo +55.65%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +47.96%
#4 Velvet Velvet +38.39%
#5 Black Phoenix Black Phoenix +34.09%
#6 Cross Cross +24.27%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.20%
#8 QANplatform QANplatform +14.54%
#9 Bitway Bitway +13.56%
#10 Perle Perle +13.38%
Coin of the day
Akedo Akedo
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Ovoca Bio plc Ovoca Bio plc

Ovoca Bio plc

OVXA
Rangering i aksjer #38531
Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc... Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc operates as a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market innovative therapies for various female sexual dysfunctions. Its primary drug candidate, BP-101, is being developed as a medical treatment for premenopausal women diagnosed with hypoactive sexual desire disorder. This compound is presently in Phase II clinical investigation in Australia and New Zealand, and has progressed to Phase III clinical trials within Russia. Beyond its core pharmaceutical work, the company also participates in mineral exploration and offers supplementary support services. The organization, originally incorporated as Ovoca Gold plc, rebranded to Ovoca Bio plc in July 2018.
Aksjekurs
$0.01142111
Sist synkronisert: 2025-03-21
Markedsverdi
$930.66K
Endring (1 dag)
0.18%
Endring (1 år)
0.00%
Land
IE
Handel Ovoca Bio plc (OVXA)

Kategori

Healthcare
Inntekter for Ovoca Bio plc (OVXA)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Ovoca Bio plc er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Ovoca Bio plc fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE